Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Medroxalol (RMI81968) is an orally active adrenergic receptor antagonist that effectively blocks both α- and β-adrenergic receptors, effectively producing antihypertensive and vasodilating effects [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 6-8 weeks | $ 1,940.00 | |
50 mg | 6-8 weeks | $ 3,110.00 |
Description | Medroxalol (RMI81968) is an orally active adrenergic receptor antagonist that effectively blocks both α- and β-adrenergic receptors, effectively producing antihypertensive and vasodilating effects [1]. |
In vitro | Medroxalol, at concentrations ranging from 0.1-10 μM over a 20-minute incubation period, exhibits antagonistic activity against both α- and β-adrenergic receptors in isolated rabbit aortic strips, as demonstrated by the Cell Viability Assay. Specifically, the assay results reveal pA2 values of 6.09 for α-adrenergic receptors and 7.73 for β-adrenergic receptors, indicating its efficacy in blocking these receptor types [1]. |
In vivo | Medroxalol treatment, administered via oral gavage at dosages of 12.5 to 50 mg/kg once daily for 12 days, demonstrates antihypertensive activity by inducing a dose-dependent decrease in blood pressure in male spontaneously hypertensive rats (SHR) [1]. |
Molecular Weight | 372.42 |
Formula | C20H24N2O5 |
CAS No. | 56290-94-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Medroxalol 56290-94-9 inhibitor inhibit